Access to Healthcare Practitioners (HCPs) continues to be restricted in this ever-evolving healthcare ecosystem. Contact with stakeholders is typically limited due to stringent anti-rep policies and their organization’s rules and guidelines.
This calls for new ways to reach these stakeholders and the evolution of pharmaceutical call planning.
This white paper explores the factors used to develop account based call plans and how pharmaceutical companies must adapt to ensure their representatives are prepared and qualified to conduct business within the account setting.
Please complete the simple form to get a copy of this white paper, and contact us at firstname.lastname@example.org with any questions.